Equities analysts predict that BioTelemetry Inc (NASDAQ:BEAT) will announce sales of $111.35 million for the current quarter, Zacks reports. Three analysts have issued estimates for BioTelemetry’s earnings, with estimates ranging from $111.06 million to $111.89 million. BioTelemetry reported sales of $101.36 million during the same quarter last year, which indicates a positive year over year growth rate of 9.9%. The company is scheduled to report its next earnings results on Wednesday, July 24th.

On average, analysts expect that BioTelemetry will report full year sales of $446.17 million for the current financial year, with estimates ranging from $445.03 million to $447.40 million. For the next fiscal year, analysts anticipate that the firm will post sales of $496.57 million, with estimates ranging from $490.37 million to $501.14 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.42. BioTelemetry had a net margin of 11.86% and a return on equity of 23.36%. The company had revenue of $103.98 million during the quarter, compared to analysts’ expectations of $104.17 million. During the same period last year, the company posted $0.39 EPS. BioTelemetry’s revenue was up 10.0% on a year-over-year basis.

A number of research analysts recently issued reports on BEAT shares. Zacks Investment Research raised shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research report on Monday, February 11th. Sidoti set a $95.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a research report on Tuesday, February 5th. Dougherty & Co reissued a “buy” rating and set a $75.00 price target (down from $81.00) on shares of BioTelemetry in a research report on Friday, April 26th. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, Benchmark set a $82.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. BioTelemetry presently has an average rating of “Buy” and a consensus price target of $79.57.

In other BioTelemetry news, Director Kirk E. Gorman sold 5,518 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $53.69, for a total transaction of $296,261.42. Following the completion of the sale, the director now directly owns 178,833 shares in the company, valued at approximately $9,601,543.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.50% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. Pearl River Capital LLC grew its stake in shares of BioTelemetry by 104.0% in the first quarter. Pearl River Capital LLC now owns 408 shares of the medical research company’s stock worth $26,000 after acquiring an additional 208 shares during the period. Financial Architects Inc bought a new stake in shares of BioTelemetry in the fourth quarter worth approximately $30,000. Citizens Financial Group Inc RI bought a new stake in shares of BioTelemetry in the first quarter worth approximately $38,000. Altshuler Shaham Ltd grew its stake in shares of BioTelemetry by 1,883.8% in the fourth quarter. Altshuler Shaham Ltd now owns 2,321 shares of the medical research company’s stock worth $42,000 after acquiring an additional 2,204 shares during the period. Finally, Huntington National Bank grew its stake in shares of BioTelemetry by 35.5% in the first quarter. Huntington National Bank now owns 680 shares of the medical research company’s stock worth $43,000 after acquiring an additional 178 shares during the period. Institutional investors and hedge funds own 88.79% of the company’s stock.

NASDAQ BEAT traded down $1.84 during trading hours on Monday, reaching $48.78. 532,649 shares of the company’s stock traded hands, compared to its average volume of 644,408. BioTelemetry has a 52-week low of $39.50 and a 52-week high of $80.92. The stock has a market cap of $1.71 billion, a P/E ratio of 25.14 and a beta of 1.32. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.99 and a quick ratio of 1.84.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Featured Article: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.